Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081448 | 0.93 | VDR (0.62) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL2083232 | 0.88 | HDAC6 (0.59) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL12844910 | 0.88 | VDR (0.48) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL2083670 | 0.86 | VDR (0.60) | VDRAR | |
| SCHEMBL2083397 | 0.85 | VDR (0.60) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL13785970 | 0.85 | VDR (0.65) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL14445480 | 0.84 | VDR (0.59) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL2084614 | 0.84 | HDAC6 (0.56) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL13203746 | 0.83 | VDR (0.70) | VDRHDAC6HDAC3HDAC1AR | |
| SCHEMBL2963724 | 0.83 | VDR (0.70) | VDRHDAC6HDAC3HDAC1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897789-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897789-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | LU JIANLIANG | 2010-03-25 | — | — | US | disclosed |
| US-7582775-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | VDR 1/4885HDAC6 4364/4885HDAC3 1738/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885HDAC6 4364/4885HDAC3 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.